Rezubio doses first cohort in Phase I trial of inhaled RZ-520
The trial is assessing the tolerability, safety, pharmacodynamics and pharmacokinetics in healthy volunteers.
Analysis
View MoreAPIs to the rescue?
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance